Company news

vTv Therapeutics Inc. news in 2025

vTv Therapeutics Inc.'s news releases, calls and decks from 2025, newest first.

View company

vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

December 18, 2025

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 6, 2025

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

October 9, 2025

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

September 15, 2025

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

September 3, 2025

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

September 2, 2025

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

August 11, 2025

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

August 7, 2025

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

June 11, 2025

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 19, 2025

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

May 15, 2025

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

March 20, 2025

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

March 17, 2025

Decks in 2025